Here is Matt Lowdon‘s weekly deals update covering news in medical technology and biotech. Headlines include news from gene therapies, cancer detection, surgical robotics and more. Congratulations to all involved. 🍾
🔔 A few months after launching its lead gene therapy into the clinic, Arbor Biotechnologies has found a European partner to come along for the ride. Italian pharma Chiesi Group is fertilizing Arbor’s rare disease efforts with a collaboration and license agreement potentially worth more than $2 billion.
🔔Miami-based DermaSensor, Inc. raises $16M Series B to support skin cancer detection device.
🔔AiM Medical Robotics, a pioneer in MRI-compatible surgical robotic systems, announced the successful closing of its $8.1 million Series A financing round. The round was led by IQ Capital and 1540 Ventures.
🔔Strasbourg-based RDS, a French MedTech company, today announced a €14 million Series A funding round for its remote monitoring and wearable patch, in order to accelerate its development in France, Germany and the broader European market.
🔔Startup developing ‘liquid bandages’ raises £4.8m. NoBACZ Healthcare is a spinout company from the University of Cambridge
🔔Deciphex, a leader in AI-powered digital pathology, has closed its Series C financing, raising €31 million to address the acute global pathology crisis.
🔔US clinical-stage biotech OncoC4, Inc. revealed it has closed a Series B financing round of nearly $50 million
🔔Danish Genmab A/S has acquired the Dutch oncology specialist Merus N.V. for US$8bn
🔔James Mackay is tending to ‘unfinished business’ with new gout biotech and $205M fundraise with Crystalys Therapeutics.
🔔An AI-driven drug discovery platform will receive a step up onto the Nasdaq via a reverse merger with a blank check company. Nanyang Biologics has been snapped up by Nasdaq-listed RF Acquisition Corp II, a special purpose acquisition company.
🔔Aerska has launched with $21 million in seed funding the European biotech will use for its mission to deliver genetic medicines to the brain.
🔔KYORIN Pharmaceutical Co., Ltd. Pharmaceutical has strengthened its autoimmune portfolio by paying $10 million upfront for the Japanese rights to Hinge Bio’s preclinical lupus drug.
🔔AstraZeneca has signed a $555 million deal with San Francisco biotech Algen Biotechnologies that will tap the latter company’s artificial intelligence platform to boost discovery of new targets in immunology.
#medicaldevices
#biotechnology
#surgicalrobotics
#cancerdetection
#genetherapy
#healthcare
